From Shanghai to Singapore: Strategic insights enable a biotech’s APAC expansion

A China-headquartered biotech with approval for an innovative ophthalmology biologic sought to expand into other APAC countries. The strategy was to target Singapore first, requiring an experienced partner to manage the regulatory submission. The biotech required support to develop their pre-submission regulatory strategy and ensure CMC readiness. The China-only approval had to be aligned to meet the requirements of Singapore’s Health Sciences Authority (HSA). ICON’s regulatory expertise and agile biotech-focused model made us the partner of choice for this project.

The HSA operates reliance-based evaluation routes for products approved by recognised reference agencies, such as the FDA, EMA, TGA, Swissmedic, Health Canada, and MHRA. However, China’s NMPA is not currently among HSA’s reference agencies. 

Accordingly, there was a high possibility of extensive queries, screening rejections, and significant delays in approval and commercialisation plans. Key CMC risks included lack of demonstrated comparability to globally accepted standards, limited GMP alignment evidence, and insufficient stability data to support shelf life under ICH conditions. Clinical risks included bridging the China-generated clinical date to demonstrate relevance to broader populations and Singapore-specific regulatory requirements. The identified gaps could result in rework, additional costs and a delayed timeline.

Another critical barrier was that the China-based biotech did not have a local legal entity in Singapore to act as their Marketing Authorisation Holder (MAH). This is a mandatory requirement without which the submission could not proceed. This created additional regulatory complexity for batch release responsibilities, pharmacovigilance, and quality oversight. Establishing a compliant MAH requires careful consideration of regulatory responsibility, operational set up and long-term commercialisation strategy. 

In common with many biotechs, the company had internal resource constraints as they were already managing a busy oncology pipeline. This compounded the risk of inefficient execution, mis-sequencing and delayed market entry. Missing the critical window to establish an early foothold outside of China could result in loss of a competitive advantage.

ICON performed a comprehensive gap assessment of the NMPA dossier alongside the HSA’s regulatory requirements. The team developed a detailed CMC, clinical gap analysis and risk assessment plan. This encompassed analytical comparability strategy, alignment to ICH requirements and identification of critical quality and clinical attributes requiring bridging justification. This exercise enabled early identification of risks and defined the regulatory pathway. ICON established that the treatment was eligible for the Abridged Evaluation Route which decreased costs, documentation requirements and review timelines. In collaboration with the sponsor, ICON’s team consolidated all activities on a prioritised roadmap to ensure efficient sequencing, minimise rework and accelerate readiness. ICON Regulatory Consulting coordinated all activities. 

ICON’s regulatory expertise strengthened the submission by:

• Aligning critical Chinese data with ICH E5 and developing scientific justification for its relevance
• Assessing ethnic sensitivity for broader applicability
• Identifying, prioritising and addressing CMC gaps for proactive mitigation

Crucially, ICON addressed a key access barrier by delivering a tailored solution through a local vendor partnership. This enabled a fully compliant MAH model with in-country license holding and on-the-ground intelligence. By leveraging strong relationships with local partners, ICON established a robust framework for the biotech’s MAH ensuring seamless regulatory submissions, effective HSA engagement and ongoing lifecycle management support.

“ICON delivered an exceptionally well-structured and professionally written consultation document that clearly reflected deep regulatory expertise and thorough risk assessment. The quality of the work and strategic insight gave us strong confidence in our approach. We greatly appreciated ICON’s outstanding support.” 

ICON transformed a complex and uncertain pathway into a clear, actionable APAC expansion strategy, enabling the client to progress confidently toward a successful submission in Singapore.

ICON’s expertise brought clarity and actionable steps to a complex, uncertain plan for regional expansion. This proactive approach and identification of regulatory and operational barriers enabled HSA engagement to proceed. 

Key impacts included:

• Reduced risk of delays and submission failure
• Faster, better informed decision-making
• Streamlined execution aligned to limited internal resources
• Reduced regulatory risk and improved submission quality
• A scalable framework for the biotech’s future APAC expansion. 

What began as a once-off project-specific engagement with ICON has expanded into a longer-term partnership supporting the biotech’s expansion into other APAC regions. In a complex, low precedent regulatory environment ICON’s attention to the minute details and multiple activities ensured the customer had a clear filing strategy for a right-first-time submission. This key competitive advantage is a significant step towards realising their asset’s full global potential. Significantly, it widens patient access to a promising new treatment.